Cat.No. KIT 036
An ELISA for the in vitro determination of human NGAL in urine and plasma.
Human NGAL (Neutrophil Gelatinase-Associated Lipocalin)
NGAL is a new early biomarker for diagnosing acute kidney injury (AKI).
Under normal conditions, NGAL levels are low in urine and plasma, but they rise sharply from basal levels in response to kidney injury to reach diagnostic levels within a very short time - as much as 24 hours or more before any significant rise in serum creatinine.
Hasse-Fielitz A, Haase M, Devarajan P (2014) Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status. Ann Clin Biochem 51:335-351
Cho E, Yang HN, Jo SK, Cho WY, Kim HK (2013) The role of urinary liver-type fatty acid-binding protein in critically ill patients. J Korean Med Sci. 28:100-105
Di NM, Ficarella A, Ricci Z, Luciano R, Stoppa F, Picardo S, Picca S, Muraca M, Cogo P (2013)Impact of severe sepsis on serum and urinary biomarkers of acute kidney injury in critically ill children: an observational study. Blood Purif 35: 172-176
Kashani K et al (2013) Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care 17:R25
Kift RL et al (2013) A comparison of the analytical performance of five commercially available assays for neutrophil gelatinase-associated lipocalin using urine. Ann Clin Biochem. 50: 236-244